Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 5, No 2 (2020)
Review article
Published online: 2020-05-22
View PDF Download PDF file
Get Citation

Material engineering for atopic dermatitis treatment

Karolina Kulig1, Wojciech Rogóż1, Aleksandra Owczarzy1, Agnieszka Szkudlarek1, Małgorzata Maciążek-Jurczyk1
DOI: 10.5603/MRJ.a2020.0012
·
Medical Research Journal 2020;5(2):110-115.
Affiliations
  1. Department of Physical Pharmacy, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska 4, 41-200 Sosnowiec, Poland

open access

Vol 5, No 2 (2020)
REVIEW ARTICLES
Published online: 2020-05-22

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 30% for children and to 17% for adults. There is observed an increasing trend of occurring AD over time in the world. Many factors contribute to the development of the disease, such as environmental, genetic and psychological factors. The proper AD treatment should be complexed and consists of skin care with emollients and pharmacological treatment. Most of the topical corticosteroids and other drugs have unpleasant side effects, therefore, developing new therapies is very useful. To minimalize side effects with a simultaneous reduction in the duration, a NPs (nanoparticles) therapy application is highly proposed. On the other hand, hydrogels and their shielding properties with high hydrating level and drug delivery capability are also widely studied. Some works report on the combination of these two solutions with promising results. Material engineering for biomedical applications is a dynamically growing field which offers new drug delivery systems (DDS). In this paper, based on the literature we discuss the new methods of AD treatment using hydrogels and nanotechnology.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 30% for children and to 17% for adults. There is observed an increasing trend of occurring AD over time in the world. Many factors contribute to the development of the disease, such as environmental, genetic and psychological factors. The proper AD treatment should be complexed and consists of skin care with emollients and pharmacological treatment. Most of the topical corticosteroids and other drugs have unpleasant side effects, therefore, developing new therapies is very useful. To minimalize side effects with a simultaneous reduction in the duration, a NPs (nanoparticles) therapy application is highly proposed. On the other hand, hydrogels and their shielding properties with high hydrating level and drug delivery capability are also widely studied. Some works report on the combination of these two solutions with promising results. Material engineering for biomedical applications is a dynamically growing field which offers new drug delivery systems (DDS). In this paper, based on the literature we discuss the new methods of AD treatment using hydrogels and nanotechnology.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

atopic dermatitis, drug delivery system, nanoparticles, hydrogels

About this article
Title

Material engineering for atopic dermatitis treatment

Journal

Medical Research Journal

Issue

Vol 5, No 2 (2020)

Article type

Review article

Pages

110-115

Published online

2020-05-22

Page views

859

Article views/downloads

874

DOI

10.5603/MRJ.a2020.0012

Bibliographic record

Medical Research Journal 2020;5(2):110-115.

Keywords

atopic dermatitis
drug delivery system
nanoparticles
hydrogels

Authors

Karolina Kulig
Wojciech Rogóż
Aleksandra Owczarzy
Agnieszka Szkudlarek
Małgorzata Maciążek-Jurczyk

References (48)
  1. Wang C, Kraus CN, Patel KG, et al. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Int J Dermatol. 2020; 59(2): 253–256.
    CrossRefPubMed
  2. Yeom M, Ahn S, Oh JY, et al. Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2020; 98: 109818.
    CrossRefPubMed
  3. Jaworek AK, Jaworek M, Makara-Studzińska M, et al. Depression and Serum Content of Serotonin in Adult Patients with Atopic Dermatitis. Adv Exp Med Biol. 2020 [Epub ahead of print].
    CrossRefPubMed
  4. Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune-related skin diseases in 2019. Expert Rev Clin Immunol. 2020; 16(2): 155–166.
    CrossRefPubMed
  5. González-Tarancón R, Sanmartín R, Lorente F, et al. Prevalence of FLG loss-of-function mutations R501X, 2282del4, and R2447X in Spanish children with atopic dermatitis. Pediatr Dermatol. 2020; 37(1): 98–102.
    CrossRefPubMed
  6. Margolis DJ, Mitra N, Wubbenhorst B, et al. Filaggrin sequencing and bioinformatics tools. Arch Dermatol Res. 2020; 312(2): 155–158.
    CrossRefPubMed
  7. Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31(1): 33–40.
    CrossRefPubMed
  8. Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy. 2020; 75(1): 63–74.
    CrossRefPubMed
  9. Fuertes E, Flohr C, Silverberg JI, et al. ISAAC Phase Three Study Group. Global Associations between UVR Exposure and Current Eczema Prevalence in Children from ISAAC Phase Three. J Invest Dermatol. 2017; 137(6): 1248–1256.
    CrossRefPubMed
  10. Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2020; 182(1): 47–54.
    CrossRefPubMed
  11. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014; 69(1): 3–16.
    CrossRefPubMed
  12. Grine L, Tochtermann G, Lapeere H, et al. Comparison of Personality Traits among Patients with Psoriasis, Atopic Dermatitis, and Stress: A Pilot Study. Dermatology. 2020 [Epub ahead of print]: 1–5.
    CrossRefPubMed
  13. Duran S, Atar E. Determination of depression, anxiety and stress (DAS) levels in patients with atopic dermatitis: a case-control study. Psychol Health Med. 2019 [Epub ahead of print]: 1–11.
    CrossRefPubMed
  14. Glatz M, Jo JH, Kennedy EA, et al. Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One. 2018; 13(2): e0192443.
    CrossRefPubMed
  15. Rademaker M, Agnew K, Andrews M, et al. Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative. Australas J Dermatol. 2020; 61(1): 9–22.
    CrossRefPubMed
  16. Thyssen JP, Berents T, Bradley M, et al. Clinical Management of Atopic Dermatitis in Adults: Mapping of Expert Opinion in 4 Nordic Countries using a Modified Delphi Process. Acta Derm Venereol. 2020; 100(1): adv00015.
    CrossRefPubMed
  17. Phan K, Charlton O, Baker C, et al. Dermatologist attitudes toward ciclosporin use in atopic dermatitis. J Dermatolog Treat. 2020 [Epub ahead of print]: 1–3.
    CrossRefPubMed
  18. Lopes A, Sokolova A, Abreu C, et al. Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options. Eur Ann Allergy Clin Immunol. 2020; 52(1): 4–14.
    CrossRefPubMed
  19. Tanei R. Atopic Dermatitis in Older Adults: A Review of Treatment Options. Drugs Aging. 2020; 37(3): 149–160.
    CrossRefPubMed
  20. Juarez MC, Grossberg AL. Phototherapy in the Pediatric Population. Dermatol Clin. 2020; 38(1): 91–108.
    CrossRefPubMed
  21. Woo TE, Sibley CD. The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis. J Am Acad Dermatol. 2020; 82(1): 222–228.
    CrossRefPubMed
  22. Alexander H, Paller AS, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. Br J Dermatol. 2019 [Epub ahead of print].
    CrossRefPubMed
  23. Blicharz L, Usarek P, Młynarczyk G, et al. Is Itch Intensity in Atopic Dermatitis Associated with Skin Colonization by ? Indian J Dermatol. 2020; 65(1): 17–21.
    CrossRefPubMed
  24. Souto EB, Dias-Ferreira J, Oliveira J, et al. Trends in Atopic Dermatitis-From Standard Pharmacotherapy to Novel Drug Delivery Systems. Int J Mol Sci. 2019; 20(22).
    CrossRefPubMed
  25. Regis E. Nanotechnologia, narodziny nowej nauki, czyli świat cząsteczka po cząsteczce. Prószyński i S-ka, Warszawa 2001.
  26. Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. Arab J Chem. 2019; 12(7): 908–931.
    CrossRef
  27. Tiwari J, Tiwari R, Kim K. Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices. Prog Mater Sci. 2012; 57(4): 724–803.
    CrossRef
  28. Tiwari A, Saraf S, Jain A, et al. Basics to advances in nanotherapy of colorectal cancer. Drug Deliv Transl Res. 2020; 10(2): 319–338.
    CrossRefPubMed
  29. Mashaghi S, Jadidi T, Koenderink G, et al. Lipid nanotechnology. Int J Mol Sci. 2013; 14(2): 4242–4282.
    CrossRefPubMed
  30. Singh D, Singh S, Sahu J, et al. Ceramic nanoparticles: Recompense, cellular uptake and toxicity concerns. Artif Cells Nanomed Biotechnol. 2016; 44(1): 401–409.
    CrossRefPubMed
  31. Gharpure S, Akash A, Ankamwar B. A Review on Antimicrobial Properties of Metal Nanoparticles. J Nanosci Nanotechnol. 2020; 20(6): 3303–3339.
    CrossRefPubMed
  32. Falagan-Lotsch P, Grzincic EM, Murphy CJ. New Advances in Nanotechnology-Based Diagnosis and Therapeutics for Breast Cancer: An Assessment of Active-Targeting Inorganic Nanoplatforms. Bioconjug Chem. 2017; 28(1): 135–152.
    CrossRefPubMed
  33. Siddique MI, Katas H, Jamil A, et al. Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects. Drug Deliv Transl Res. 2019; 9(2): 469–481.
    CrossRefPubMed
  34. Zhuo F, Abourehab MAS, Hussain Z. Hyaluronic acid decorated tacrolimus-loaded nanoparticles: Efficient approach to maximize dermal targeting and anti-dermatitis efficacy. Carbohydr Polym. 2018; 197: 478–489.
    CrossRefPubMed
  35. Pandey M, Choudhury H, Gunasegaran TAP, et al. Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting. Drug Deliv Transl Res. 2019; 9(2): 520–533.
    CrossRefPubMed
  36. Huang PH, Tseng CH, Lin CY, et al. Preparation, characterizations and anti-pollutant activity of 7,3',4'-trihydroxyisoflavone nanoparticles in particulate matter-induced HaCaT keratinocytes. Int J Nanomedicine. 2018; 13: 3279–3293.
    CrossRefPubMed
  37. Kang JH, Chon J, Kim YI, et al. Preparation and evaluation of tacrolimus-loaded thermosensitive solid lipid nanoparticles for improved dermal distribution. Int J Nanomedicine. 2019; 14: 5381–5396.
    CrossRefPubMed
  38. Wagner I, Geh KJ, Hubert M, et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec. 2017; 181(5): 118.
    CrossRefPubMed
  39. Kang H, Kim S, Lee KH, et al. 5 nm Silver Nanoparticles Amplify Clinical Features of Atopic Dermatitis in Mice by Activating Mast Cells. Small. 2017; 13(9).
    CrossRefPubMed
  40. Goindi S, Kumar G, Kaur A. Novel flexible vesicles based topical formulation of levocetirizine: in vivo evaluation using oxazolone-induced atopic dermatitis in murine model. J Liposome Res. 2014; 24(3): 249–257.
    CrossRefPubMed
  41. Harrison IP, Spada F. Hydrogels for Atopic Dermatitis and Wound Management: A Superior Drug Delivery Vehicle. Pharmaceutics. 2018; 10(2).
    CrossRefPubMed
  42. WICHTERLE O, LÍM D. Hydrophilic Gels for Biological Use. Nature. 1960; 185(4706): 117–118.
    CrossRef
  43. Szekalska M, Sosnowska K, Tomczykowa M, et al. In vivo anti-inflammatory and anti-allergic activities of cynaroside evaluated by using hydrogel formulations. Biomed Pharmacother. 2020; 121: 109681.
    CrossRefPubMed
  44. Jeong JiH, Back SK, An JH, et al. Topical film prepared with Rhus verniciflua extract-loaded pullulan hydrogel for atopic dermatitis treatment. J Biomed Mater Res B Appl Biomater. 2019; 107(7): 2325–2334.
    CrossRefPubMed
  45. Kircik L. The effect of desonide hydrogel on pruritis associated with atopic dermatitis. J Drugs Dermatol. 2014; 13(6): 725–728.
    PubMed
  46. Wang W, Wat E, Hui PCL, et al. Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment. Sci Rep. 2016; 6: 24112.
    CrossRefPubMed
  47. Augustin M, Goepel L, Jacobi A, et al. Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study. Clin Cosmet Investig Dermatol. 2017; 10: 373–384.
    CrossRefPubMed
  48. Napimoga MH, Clemente-Napimoga JT, Machabanski NM, et al. The 15d‑PGJ2 hydrogel ameliorates atopic dermatitis through suppression of the immune response. Mol Med Rep. 2019; 19(6): 4536–4544.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl